Early kidney function changes may not explain heart risk with dapagliflozin and semaglutide treatment in real-world patients

Changes in estimated glomerular filtration rate (eGFR) may influence heart failure and myocardial infarction outcomes when using dapagliflozin plus semaglutide.

• Cardiovascular-kidney-metabolic (CKM) syndrome involves heart failure, myocardial infarction, kidney disease, diabetes, and obesity.
• SGLT2 inhibitors and GLP-1 receptor agonists are associated with improved cardiovascular and renal outcomes.
• The specific mechanisms of how combination therapy with dapagliflozin and semaglutide affects these outcomes remain unclear.
• The study aims to assess whether early changes in eGFR mediate the effects of the combination therapy.

Simplified